Trial · NCT02014584
Outcomes58
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 58
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period | 24 weeks | Safety Population: all randomized participants who received at least one dose of study treatment. | Participants | NUMBER |
| PRIMARY | Number of Participants With AE Related to Sexual Function in the Open-label Treatment Period | 24 weeks | Open-Label Period Population: all participants who entered the open-label period. | Participants | NUMBER |
| PRIMARY | Number of Participants With AE Related to Sexual Function for the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined: all participants who entered the OL Period and taken Dutasteride in both the DB and the OL periods. | Participants | NUMBER |
| SECONDARY | Duration and Persistence of AEs Related to Sexual Function in the Double-blind Treatment Period | 24 weeks | Safety Population | Days | MEAN |
| SECONDARY | Duration and Persistence of AEs Related to Sexual Function in the Open-label Treatment Period | 24 weeks | Safety Population | Days | MEAN |
| SECONDARY | Duration and Persistence of AEs Related to Sexual Function in the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined population | Days | MEAN |
| SECONDARY | Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Double-blind Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
| SECONDARY | Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Open-label Treatment Period | 24 weeks | Open-Label Period Population | Participants | NUMBER |
| SECONDARY | Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs, Serious AEs (SAEs) and Possible Suicidality Related Adverse Events (PSRAEs) in the Double-blind Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs, SAEs and PSRAEs in the Open-label Treatment Period | 24 weeks | Open-Label Period Population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs, SAEs and PSRAEs in the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined population | Participants | NUMBER |
| SECONDARY | Number of Participants With Treatment-related AEs in the Double-blind Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Treatment-related AEs in the Open-label Treatment Period | 24 weeks | Open-Label Period Population | Participants | NUMBER |
| SECONDARY | Number of Participants With Treatment-related AEs in the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs of Special Interest in the Double-blind Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs of Special Interest in the Open-label Treatment Period | 24 weeks | Open-Label Period Population | Participants | NUMBER |
| SECONDARY | Number of Participants With AEs of Special Interest in the Double-blind and Open-label Combined Periods | 48 weeks | Dutasteride DB/OL Combined population | Participants | NUMBER |
| SECONDARY | Suicidality Assessment Score by Using the Columbia Suicide Severity Rating Scale (C-SSRS) in the Double-blind Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
| SECONDARY | Suicidality Assessment Score by Using the Columbia Suicide Severity Rating Scale (C-SSRS) in the Open-label Treatment Period | 24 weeks | Safety Population | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02014584/outcomes